Published in:
01-08-2006 | LETTER TO THE EDITORS
CSF-air-exchange for pharmacorefractory status epilepticus
Authors:
Dr. med Martin Köhrmann, Dr. med Hagen B. Huttner, Dr. med Daniel Gotthardt, Dr. med Simon Nagel, Dr. med Christian Berger, Prof. Dr. Stefan Schwab
Published in:
Journal of Neurology
|
Issue 8/2006
Login to get access
Excerpt
Sirs: Refractory status epilepticus (RSE) is defined as a status epilepticus (SE) that fails to respond to first- and second-line therapy [
2]. It occurs in up to 40% of patients with SE [
5]. Despite advances in specific treatment as well as general intensive care management of those patients morbidity and mortality remain high. Up to half of the patients die and only about 30% return to their pre-morbid functional baseline [
2]. With increasing duration SE becomes less likely to be controlled by conventional antiepileptic drugs [
1,
5] and there are few data about the treatment course after the failure of first-, second- and even third-line treatment. The poor prognosis at this stage justifies the use of unconventional treatment attempts. …
